Reliis has a clear vision of creating innovative solutions by leveraging safe and effective medicines to address unmet clinical needs, with significant commercial value.
What sets Reliis apart is its strong emphasis on collaboration with renowned medical professionals and clinicians. This distinctive approach, combined with a highly dedicated and knowledgeable team, has established Reliis as an emerging player in the industry.
One of Reliis' key strategies is drug reformulation, which enables a faster and more cost-effective pathway for regulatory approval and commercialisation compared to traditional novel drug development programs.
To ensure the highest level of expertise and insight, Reliis maintains an esteemed Scientific Advisory Board composed of members who actively engage and collaborate with various stakeholders, including medical professionals, researchers, and pharmaceutical experts. By drawing from their practical experience with patients, Reliis' specialist clinicians can identify drugs that enhance patient care and target unmet medical needs.
Currently, Reliis has a robust product pipeline consisting of several high-priority drugs and a medical device. These initiatives highlight Reliis' commitment to advancing healthcare through innovation and addressing critical challenges in patient treatment and care.
Company Details
- Employees
- 6
- Founded
- -
- Address
- 22 Stirling Hwy, Level 1,australia
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.reliis.com.au
- Keywords
- insight.
- HQ
- Nedlands, Western Australia
Reliis Questions
Reliis's website is http://www.reliis.com.au
Reliis's LinkedIn profile is https://au.linkedin.com/company/reliis-limited
Reliis has
6 employees.
View email and phone details for 6
employees at Reliis.
Reliis's industry is
Biotechnology Research
Reliis's categories are Biotechnology Research
Reliis's founding year is 2019
